Global Ocular Drug Delivery System Market Size, Share, and COVID-19 Impact Analysis by Technology (Topical, Iontophoresis, Ocular Insert [Erodible and Non-Erodible], Intraocular Implants [Biodegradable and Non-Biodegradable], In Situ Gel & Punctal Plugs, and Others), Formulation Type (Liposomes & Nanoparticles, Solution, Emulsion, Suspension, and Ointment), by Disease Type (Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Macular Degeneration, Cataract, Diabetic Macular Edema, and Others), and by End User (Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers, and Homecare Settings), by Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 – 2030)Industry: Healthcare
Global Ocular Drug Delivery System Market Statistics & Facts
- The Global Ocular Drug Delivery System Market Size was valued at USD 69.1 Billion in 2022
- The Market is Growing at a CAGR of 7.35% from 2022 to 2032
- The Worldwide Ocular Drug Delivery System Market Size is expected to reach USD 140.5 Billion by 2032
- Asia Pacific is expected To Grow the fastest during the forecast period
An eye is a valuable organ which is impacted by various health problems. Such diseases can not only affect the body but also decrease the vision of a person. Thus, there are various drug delivery systems present in the market which help in treating such eye diseases. Due to efficient protective mechanism of the eye, the market consists of different ophthalmic drugs. In fact, around 70% of the eye dosages that are available in the market are sold in the form of ointments and eye drops. However, these ointments and drops easily drain away from the ocular cavity due to the tears flowing from the eyes. Therefore, novel and advanced pharmaceutical ophthalmic formulations are launched in the developing nations. The customers can get these formulations in the form of nanoparticle, microemulsion, iontophoresis, liposome, and ocular inserts.
Get more details on this report -
Impacts of COVID 19 on Global Ocular Drug Delivery System Market
COVID 19 pandemic is anticipated to affect the growth of the global ocular drug delivery system market. The sudden reduction in the office visits of the physicians and decline in the number of prescription and the purchase of eye drop is anticipated to affect the market growth amidst the onset of the pandemic. Having said that the availability of the COVID 19 vaccines and sppedy vaccination programs are anticipated to help the market in getting recovered by upcoming one to two years. Apart from this, the launch of eye treatment products, both high end and generic are anticipated to hamper the market growth. In addition, the supply chain disruption, delay in research and development activities and change in priority of reputed companies will hamper the overall market.
Global Ocular Drug Delivery System Market Report Coverage
|Market Size in 2021:||USD 69.1 Billion|
|2030 Value Projection:||USD 140.5 Billion|
|Historical Data for:||2018-2021|
|No. of Pages:||200|
|Tables, Charts & Figures:||110|
|Segments covered:||By Technology, by Disease Type, by End User, by Region.|
|Companies Covered:||Valeant Pharmaceuticals International, Inc., Taiwan Liposome Company, Ltd., Ocular Therapeutix, Inc., Graybug Vision Inc., EyeGate Pharma, Clearside Biomedical, Inc., Alimera Sciences, Envisia Therapeutics, Allergan, Plc, AbbVie Inc.|
|Pitfalls & Challenges:||COVID-19 Empact, Challenge, Future, Growth, & Analysis|
Get more details on this report -
Key Market Drivers
Introduction of new products to drive the market
In order to get rid of the ocular drug delivery barriers as well as to improve bioavailability, different conventional as well as novel drug delivery systems have been introduced like emulsion, ointments, aqueous gels, suspensions, liposomes, nanomicelles, implants, dendrimers, contact lens, and nanoparticles. Not only this but also the key market players are focussed to develop tools which help in improving the efficacy of spatiotemporal drug administration. For instance, in May 2017, pSivida Corp. has made an announcement about its positive 12 months follow up data of third phase trials for Durasert which helps to improve the treatment of posterior uneitis infection.
Increasing investment in R&D to propel the market
The market need huge amount of investment at the developmental stages of advanced ocular drug delivery technologies. The increasing number of new entrants, the expenses related to research and development are anticipated to increase at a significant rate owing to the collaborations and licensing agreements with various research institutes. In fact various pharmaceutical companies of developed economies are already spending huge amount to develop new technologies which is boosting the market growth.
Key Market Challenges
Ocular implants and inserts offer certain benefits like greater dissolution area, high corneal penetration, and release of medication but the sensation of foreign bodies in the eye owing to the solidity of the implants will result in discomfort in eye along with drug dilution, irritation, and excessive lachrymation which is going to restrain the market. Apart from this, the reduction in the patient compliance, adherence to novel ocular therapies owing the high cost associated with it will hamper the market growth.
The global ocular drug delivery system market is segmented into technology, formulation type, disease type, end users, and technology. Among technology, the market is segmented into topical, iontophoresis, ocular insert, intraocular implants, insitu gel and punctal plugs, others. On the basis of formulation type, the global ocular drug delivery system market is segmented into liposomes and nanoparticles, emulsion, solution, suspension, ointment. Based on disease type, the market is segmented into glaucoma, diabetic retinopathy, dry eye syndrome, macular degeneration, cataract, diabetic macular edema, others. On the basis of end users, the market is bifurcated into hospitals, ambulatory surgical centers, ophthalmic clinics, homecare settings.
North America is dominating the market with the largest market share over the forecast period.
Get more details on this report -
North America is dominating the market with the largest market share and is going to continue its dominance over the forecast period owing to the increasing research collaboration and license agreement for clinical products. Apart from this, the increasing technological advancements provides opportunities to the companies in delivering the medicines related to ocular tissues.
Europe, on the other hand is witnessing the fastest market growth over the forecast period due to the common clinical developments, improvements in drug development, increasing demand in extensive product portfolios, and production capacities are some of the factors which are boosting the regional growth.
Recent Market Developments
- In 2020, Ocular Therapeutix and AffaMed Therapeutics has made an announcement about their collaboration and license agreement for DEXTENZA and OTX-TIC in Asia.
List of Key Companies
- Valeant Pharmaceuticals International, Inc.
- Taiwan Liposome Company, Ltd.
- Ocular Therapeutix, Inc.
- Graybug Vision Inc.
- EyeGate Pharma
- Clearside Biomedical, Inc.
- Alimera Sciences
- Envisia Therapeutics
- Allergan, Plc
- AbbVie Inc.
This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the global Ocular Drug Delivery System Market based on the below-mentioned segments:
Ocular Drug Delivery System Market, Technology Analysis
- Ocular insert
- Intraocular implants
- Insitu gel
- Punctal plugs
Ocular Drug Delivery System Market, Formulation Type Analysis
- Liposomes and nanoparticles
Ocular Drug Delivery System Market, Disease Type Analysis
- Diabetic retinopathy
- Dry eye syndrome
- Macular degeneration
- Diabetic macular edema
Ocular Drug Delivery System Market, End User Analysis
- Ambulatory surgical centers
- Ophthalmic clinics
- Homecare settings
Ocular Drug Delivery System Market, Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa.
Need help to buy this report?